Abstract 4672
Background
KRAS, NRAS and BRAF mutation testing for metastatic colorectal cancer (mCRC) is essential to guide treatment and prognostication. Multiple gene profiling assays are available, each with differing tumour sample size/quality requirements and turnaround time (TAT). Many UK hospitals send samples to off-site labs for profiling. A rapid TAT is desirable to plan appropriate chemotherapy +/- biologics from cycle one, as well as providing certainty and satisfaction for patients and clinicians.
Methods
This study was conducted at 2 UK tertiary cancer centres (University College London Hospital and Mount Vernon Hospital), comparing a pathway where gene profiling of mCRC was performed off-site using an NGS platform versus on-site testing using the Idylla platform (Biocartis, Mechelen, Belgium). Up to 50 patients were included in each group with 8 of the Idylla tests being used for samples that had failed with the NGS platform.
Results
Mutational profiling results for the whole cohort that were successfully tested (n = 84) showed 26% (22/84) were wildtype for KRAS/NRAS/BRAF, 62% (52/84) KRAS mutated, 2% (2/84) NRAS mutated, 10% (8/84) BRAF mutated. The median TAT in days (median, interquartile range (IQR)) of the on-site Idylla pathway was shorter than the off-site NGS pathway (4, 1 - 6 vs. 15, 13-17; p = <0.0001). In the off-site group median time from request to receipt of sample was 3 days (IQR 2 - 5) and median time from receipt to result was 10 days (IQR 9 - 13). Test failure rate was significantly higher with the NGS test (30%, 15/50) compared to the Idylla test (2%, 1/50) (p = 0.0001). 8 samples that had failed testing with the NGS platform, due to insufficient/low quality of sample, were all successfully tested with the Idylla platform.
Conclusions
For gene profiling of mCRC, on-site testing with the Idylla platform significantly shortened the TAT, lowered failure rate and was able to test more sub-optimal samples compared to off-site NGS testing. Updated results integrating these data with tumour location, MMR status and treatment outcomes will be presented at ESMO 2019.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Biocartis provided the Idylla test kits for this study without charge.
Disclosure
N. Bhuva: Honoraria (self), supported in attending international meetings: Amgen; Honoraria (self), supported in attending international meetings: Bristol-Myers Squibb. K. Shiu: Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Roche; Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Merck Group; Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Servier; Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
2786 - Development of a living organoid biobank derived from colorectal cancer patients: towards personalized medicine
Presenter: Federica Papaccio
Session: Poster Display session 2
Resources:
Abstract
3351 - Microsatellite Instability Detection in Colorectal Cancer: 44-Center Comparison between the Idylla MSI Assay and Routine Molecular and Immunohistochemistry Tests on Formalin-Fixed Paraffin-Embedded Tissue
Presenter: Xavier Matias-guiu
Session: Poster Display session 2
Resources:
Abstract
4901 - Expression profile of EPHB3 and its prognostic significance in colorectal cancer progression (Running head: Prognostic value of EPHB3 in colorectal cancers)
Presenter: Bogun Jang
Session: Poster Display session 2
Resources:
Abstract
5030 - A pan-ErbB family inhibitor, AF8c, promotes apoptosis by DR5/Nrf2 activation via ROS in colorectal cancer cells
Presenter: Soyeon Jeong
Session: Poster Display session 2
Resources:
Abstract
5053 - Frequent BRAF, GNAS and SMAD4 mutations identified in Colorectal Mucinous Carcinomas
Presenter: Sun Mi Lee
Session: Poster Display session 2
Resources:
Abstract
5220 - Impact of CCL4 knockout using CRISPR Cas-9 technology on colorectal tumor progression
Presenter: Roba Barakat
Session: Poster Display session 2
Resources:
Abstract
5330 - Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer
Presenter: Ida Buhl
Session: Poster Display session 2
Resources:
Abstract
5515 - WRN mutated Colorectal Cancer (CRC) is characterized by a distinct molecular and immunological profile
Presenter: Andreas Seeber
Session: Poster Display session 2
Resources:
Abstract
5716 - Mutation analysis of B2M gene in colorectal cancer patients with microsatellite instability
Presenter: Ivana Kašubová
Session: Poster Display session 2
Resources:
Abstract
870 - Selective Wnt/β-catenin small-molecule inhibitor CWP232228 impairs tumor growth of colon cancer
Presenter: Jin Young Kim
Session: Poster Display session 2
Resources:
Abstract